Interpace Biosciences (IDXG) Misses Q2 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
August 15, 2022 4:05 PM EDT Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® 2022 Year to Date Net Loss Improves by $1.5... More



